News
Novo Nordisk warns copycat drugs continue weighing on sales
Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales and lawmakers push for lower prices. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani outlines the latest and shares what she learned from her interview with Novo Nordisk CFO Karsten Munk Knudsen.
The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback